EP0215081A1 - Preparations of immunoglobulines presenting high titres of blocking antibodies - Google Patents
Preparations of immunoglobulines presenting high titres of blocking antibodiesInfo
- Publication number
- EP0215081A1 EP0215081A1 EP19860901887 EP86901887A EP0215081A1 EP 0215081 A1 EP0215081 A1 EP 0215081A1 EP 19860901887 EP19860901887 EP 19860901887 EP 86901887 A EP86901887 A EP 86901887A EP 0215081 A1 EP0215081 A1 EP 0215081A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- igg
- preparations
- approximately
- solution
- advantageously
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 63
- 230000000903 blocking effect Effects 0.000 title claims description 11
- 239000013566 allergen Substances 0.000 claims abstract description 11
- 229920000642 polymer Polymers 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000002244 precipitate Substances 0.000 claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 230000001476 alcoholic effect Effects 0.000 claims description 13
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 13
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 12
- 239000000194 fatty acid Substances 0.000 claims description 12
- 229930195729 fatty acid Natural products 0.000 claims description 12
- 150000004665 fatty acids Chemical class 0.000 claims description 12
- 238000001556 precipitation Methods 0.000 claims description 12
- 238000005194 fractionation Methods 0.000 claims description 11
- 108060003951 Immunoglobulin Proteins 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 102000018358 immunoglobulin Human genes 0.000 claims description 9
- 238000000502 dialysis Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000001506 calcium phosphate Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 229960002446 octanoic acid Drugs 0.000 claims description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 5
- 229940078499 tricalcium phosphate Drugs 0.000 claims description 5
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims description 5
- 235000019731 tricalcium phosphate Nutrition 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 230000003381 solubilizing effect Effects 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- -1 tricalcium phosphate Chemical class 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000001698 pyrogenic effect Effects 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 239000008174 sterile solution Substances 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 description 9
- 208000010668 atopic eczema Diseases 0.000 description 9
- 238000000586 desensitisation Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 7
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229960004784 allergens Drugs 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 241000238876 Acari Species 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000001932 seasonal effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000001690 Factor VIII Human genes 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 229940074608 allergen extract Drugs 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 229940046528 grass pollen Drugs 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 240000004585 Dactylis glomerata Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000005218 dilaceration Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 description 1
- 235000021156 lunch Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940079938 nitrocellulose Drugs 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the subject of the invention is preparations of immunoglobulins having in particular high titers of antiallergenic blocking antibodies, their preparation and their applications for the treatment of allergies.
- Allergic manifestations are linked to the presence of antibodies of the IgE or reactin type present on the surface of the effector cells of the immunity and in the circulating blood.
- allergen-specific IgE antibodies are present at high levels in sensitized subjects. Antibodies of the IgG type directed against these same allergens exert a protective effect with respect to the anaphylactic reactions arising from the meeting of IgE and allergens. These IgG antibodies are called blocking antibodies * . Their presence can be demonstrated in the serum of subjects who do not have an allergic reaction. Their rate rises during desensitization cures with allergen extracts (pollens, mites, or venoms of hymenoptera), their rise being concomitant with the decrease in clinical manifests. 5
- the precipitate which forms contains the fractions I (fibrinogen, factor VIII) and II + III (IgG, factors II, VII, IX, X and the and J globulins).
- the preparations based on IgG used in therapy are generally obtained from fractions II + III.
- the inventors have found that by treating under set conditions the entire precipitate A , it is possible to select preparations based on IgG with a higher titer of anti-blocking antibodies. allergens, making it possible to reduce allergic manifestations with greater efficiency.
- the invention therefore aims to provide new preparations based on IgG having immunomodulatory anti-allergenic properties.
- the preparations based on IgG according to the invention are characterized in that they have a titer in IgG of subclass 4, or IgG 4, of at least en ⁇ about 4% and in anti-allergenic blocking antibodies, in particular anti-pollen and anti-mite at least about 20 u / ml of preparation approximately, generally at least about 15 u / ml.
- the IgG preparations of the invention have, in addition to an IgG 4 titer of at least about 4 **, a level of polymer chains of at least about 10%.
- polymer is understood to mean in the following a chain of IgG monomer units, whatever their mode of interaction.
- the IgG-based preparations of the invention have, in addition to their titer in IgG 4 of at least about 4%, and their level in polymer chains of at least about 10% , anti-allergenic blocking antibody titers, in particular anti-pollen and anti-mite approximately 20 u / ml of preparation, generally at least approximately 15 u / ml.
- the above preparations contain on average 80 to 90%, in particular approximately 85% of IgG, 7 to 15%, in particular 10% in approximately IgA, and 3 to 8., especially around 5% of Ig.
- the invention also relates to a process for the fractionation of IgG preparations meeting the characteristics defined above.
- the fractions of IgG obtained by alcoholic precipitation of human plasma are subjected to the action of a saturated linear fatty acid, preferably from C4 to C12, and the soluble part is recovered.
- cryoprecipite contains an important part in particular Factor VIII, fibrinogen, fibronectin.
- the supernatant of cryoprecipite can be used in place of plasma for the preparation of precipitate A ,.
- the solution collected is subjected to at least one purification step.
- the IgG fractions used as starting material are of the type of those resulting from alcoholic fractionation of human plasma using 95% ethanol, in quantity sufficient for a final concentration of 19 to 22%, at pH 5.85, with gradual lowering of the temperature down to - 10 * C.
- Precipitate A is redissolved for the purposes of fractionation using saturated fatty acid.
- the saturated fatty acid is added at a rate of approximately 10 to 50 g / l, preferably 20 g / l to the tam ⁇ pon solution containing precipitate A, for a concentration of this solution in proteins of the order from 20 to 30 g / 1, preferably about 25 g / 1.
- the fatty acid is added in the form of an emulsion to the buffer solution.
- the precipitate formed is collected, for example, by centrifugation, for the purposes of other industrial uses.
- the supernatant which contains the desired fractions is recovered.
- a particularly preferred fatty acid making it possible to protect IgG with great selectivity, consists of caprylic acid.
- the fatty acid solution obtained is advantageously subjected to at least one pu ⁇ rification step.
- an adjuvant endowed with an affinity for fatty acids in particular, a salt such as tri-calcium phosphate.
- a salt such as tri-calcium phosphate.
- the pH is advantageously adjusted to about 6.5.
- the excess adjuvant is removed, for example, by centrifugation and the solution thus clarified is recovered and filtered, for example on activated carbon.
- the fatty acid solution is directly filtered, for example, on active char ⁇ without carrying out the step of adding tricalcium phosphate.
- Appropriate methods include alcoholic precipitation or a separation process based on the size difference between Ig and fatty acids such as dialysis, ultrafiltration or tangential ultrafiltration.
- the pH of the treated solution is advantageously adjusted to approximately 7.
- Satisfactory conditions for alcoholic precipitation include the addition of alcohol, advantageously ethanol, to a final concentration of approximately 20 to 40%, in particular of the order of 30%, at a temperature below ambient, preferably on the solution cooled to about 0 ° C, the temperature is lowered to -10 ° C to -15 ° C, especially -12 * C. during the addition of alcohol.
- the precipitate formed is collected.
- the clarified solution advantageously IgG mentioned above or the precipitate collected 1'issue of alcohol precipitation are felicituse ⁇ ment processed to have preparations jecta- i ble -
- This treatment includes an operation such as dialysis or ultrafiltration.
- the high titers of anti-allergenic blocking antibodies of the preparations of the invention and, according to another aspect, their high content of IgG polymer make them particularly suitable for the treatment of allergies. Their interest is further increased due
- the invention therefore also relates to the application of the preparations defined above, as active principles of medicaments.
- Double-blind clinical experiments carried out with the preparations of the invention, injected into a sensitized patient, have shown the efficacy of these preparations in passive immunotherapy and in part have made it possible to significantly reduce the allergic manifestations observed in seasonal diseases.
- the medicaments of the invention can be used for the treatment of allergic conditions, in particular seasonal pollinosis or seasonal or non allergic rhinitis due to pollen or house dust.
- These drugs constitute desensitization adjuvants which are particularly advantageous at the start of desensitization by reinforcing and supplementing desensitization, by allowing the amounts of allergens injected to progress more rapidly and by avoiding the use of corticosteroid therapy.
- This passive immunotherapy does not interfere with active immunotherapy (desensitization).
- the injection of anti-allergen IgG antibodies does not prevent the rise of IgG antibodies observed during desensitization.
- the drugs of the invention can therefore be used in conjunction with desensitization treatments, whether old or recent.
- the advantage of the medicaments of the invention is more important during a resurgence of allergic manifestations after a viral disease having led to a temporary functional immuno-depression, of aperiodic spasmodic coryza and of rhino-tracheobron- allergic chites due in particular to house dust.
- the medicaments of the invention are injectable intramuscularly.
- sterile, nonpyrogenic, non-toxic preparations of pH 6, 4 to 7.2 approximately, advantageously containing around 100 to 170 g / l of total protein.
- Their antibody activity is greater than 15 u / ml as anti-pollen and greater than 15 u / ml as anti-mites.
- the electrophoretic purity of these preparations is greater than approximately 90% and the osmolarity is of the order of 250 to 500 mOsm / l.
- solutions advantageously contain an antiseptic, preservative agent such as sodium ercurothiolate. Doses less than or equal to 1 for About 10,000 of this agent is found to be suitable. They also contain a solubilising and stabilizing agent such as glycocolle. Appropriate glycocolle concentrations are of the order of 18 to 25 g / l. The sodium and chloride contents> are approximately
- the dosages which can be used are given below in the case of: a) moderate allergic manifestations, and b) slight immunodeficiencies of immunomodulation disorders or allergic manifestations severe: a)
- the attending physician will reserve the right, if the case arises, to modify the above dosage, in accordance with specific cases.
- Example n'1 process for obtaining a fraction of I ⁇ G according to the invention
- the precipitate A. which contains the fractions I + II + III is in the form of a paste. 2) Caprylic fractionation a) re-solution
- the precipitate is redissolved in an acetic buffer / acetate mixture of pH 4.8-4.9 obtained by mixing a 0.05 M solution of acetic acid and a 0.05 M solution of sodium acetate.
- 9 l of buffer are used per kg of dough. It serves ob ⁇ progressive dilaceration of the pulp in the buffer at a temperature of 20 to 22 ° C.
- the mixture is left for about 2 hours at rest, for the purpose of homogenization.
- the protein level is around 25 g / l.
- caprylic precipitation ⁇ addition of caprylic acid.
- caprylic acid (99% purity - ref. 193- erck) are added, with stirring. After the end of the introduction, the stirring is continued for another 45 minutes.
- an emulsion containing 20 g / l of caprylic acid (99% purity - ref. 193-Merck) is added, with stirring, to the protein solution. Stirring is continued until the appearance of a protein precipitate, the duration of this operation being in this case reduced. ⁇ : centrifugation.
- the pH of the supernatant is adjusted to 6.5 using 1N NaOH.
- ⁇ addition of tricalcium phosphate.
- Tricalcium phosphate is added in an amount of 2 g / l of supernatant and the mixture is stirred for 30 minutes. ⁇ : centrifugation.
- the phosphate is removed by centrifugation carried out under the above conditions. ⁇ : filtration.
- the supernatant is filtered on plates containing activated carbon (for example plates of Seitz AKS4).
- the operation lasts approximately 1 hour.
- ⁇ pH adjustment.
- Ethanol qs 30% is added to the solution precooled to 0 # C. During the addition of alcohol, we - lower the temperature to -12 * C. According to an alternative embodiment of the method according to the invention, this precipitation can be replaced by an ultrafiltration as described below in step ⁇ . ⁇ : centrifugation.
- the solution is first centrifuged with a flow rate of 30 l / h (a Sharples AS 16 device is used).
- the precipitate is redissolved at a rate of 5 l / kg in 60 l of NaCl buffer: 8 g / 1, glycine: 4.5 g / 1 (in the case of dialysis) or 11 g / 1 (in the case of l 'ultra ⁇ filtration).
- the pH is adjusted to 7.5 if necessary.
- the protein level is around 50 g / l. ⁇ -. dialysis or ultra iltration.
- the solution previously filtered, is dialyzed against NaCl (4.5 g / 1) at + 4 "C for approximately 10 hours.
- the protein level (approximately 140 g / 1) is checked.
- the osmolarity of the solution is adjusted to approximately 300 mOsm / 1 using glycine (11 g / 1).
- Sodium merthiolate (1 p 10 000) is added, then filtered sté ⁇ rilly on a filter with pore diameters of 0.22 ⁇ .
- the protein level Prior to distribution in a syringe, the protein level is adjusted to a minimum of 100 g / l (in practice 105 to 100 g / l).
- the doses of salts, glycocolle and merthiolate are supplemented according to dilution, then they are filtered sterile. These preparations are preferably stored at a temperature of the order of +2 to +6 * C.
- the product obtained in step ⁇ described above is directly filtered on plates containing activated carbon, according to the method described in step ⁇ above, without going through steps ⁇ and ⁇ above, in particular when the supernatant is not present in a milky or opalescent form.
- IgG 4 is constituted by a pool of 50 healthy blood donors whose IgG 4 level is 0.4 g / 1.
- the IgG preparations according to the invention contain on average 85% of IgG, 10% of IgA and 5% of IgM. Their IgG 4 level is greater than or equal to 4
- the control plasma pool contained 3% IgG 4.
- Anti-allergenic antibodies are measured by a radioimmunological test in solid phase.
- Nitro-cellulose disks on which the allergen extracts have been covalently coupled are incubated with dilutions of seru s or immunoglobulins. After several washes, the discs are incubated with the staphylococcal protein labeled with iodine 125 (Department of Radioisotopes. CNTS).
- Protein A binds with a high affinity to the Fc part of 93% of human IgG. After 18 h of contacts, the unbound protein A is eluted by a series of washes.
- the amount of protein A linked to IgG is measured by a gamma radiation counter and expressed in% relative to the total amount of radioactivity introduced into the reaction.
- the allergens extracted from grass pollen are absorbed on microtiter plates and then brought into contact with solutions of the invention.
- the presence of IgG fixed by allergens is revealed by an immunoglobulin labeled with alkaline phosphatase or peroxidase.
- Sigmoidal curves are obtained by expressing the optical density as a function of the dilution of the solutions.
- the activity of a serum pool of 100 donors (2 ml of each serum) serves as a reference and contains by definition 1 unit / ml. It is measured with dilutions of serum between 1/200 and 1/25. A reference curve is established between the dilution of the serum pool and the percentage of binding of protein A-
- the therapeutic gamma globulin solutions are diluted so as to obtain a percentage of protein fixation corresponding to dilutions of approximately 1/100 of the pool of sera.
- IgG antibodies are assayed for their activity vis-à-vis at least one extract of grass pollen (phleum pratense, or Dactylis glomerata) and an extract of mites (Der atophagoids pteronyssinus).
- the anti-allergenic blocking antibody titer of the IgG preparations according to the invention is at least 15 u / ml anti-pollen and 15 u / ml anti-mites.
- the average of the anti-pollen activity of 16 batches of preparation according to the invention is 23 u / ml, the level of anti-mites being identical or slightly higher Rate of polymers Permeation chromatography is carried out with a gel separating PM proteins between 20,000 and 350,000 daltons.
- AcA 34 (LKB) 100 g of proteins are deposited in 2.5 ml.
- the elution rate is 20 ml / h.
- the peaks are detected at 280 mm (measurement of the optical density " ).
- the surface is evaluated by plani etry. The results obtained show that the polymer levels of the IgG preparations of the invention are greater than 10% (average of 5 batches 15%) while the fractions of immunoglobulins fractionated by alcohol Q rarely exceed 5% (average of 13 batches 4.5%).
- Example No. 2 results of testing cli ⁇ lunches made with solutions prepared according 1'invention.
- a series of intramuscular injections of preparation according to the invention was carried out, at a rate of 20 ml / week, for 5 weeks.
- the preparation has been used in allergic subjects, without prejudging the original link of the allergy with pollens or mites.
- Activity was assessed by daily observation of the symptoms of the disease.
- Clinical manifestations (nasal, ocular and respiratory) were noted.
- Out of 33 patients subjected to this treatment 15 very good results were obtained, 10 good results, 8 failures were observed.
- the placebo group differs from the group of patients treated with the preparation according to the invention by a statistically lower "symptom score" during the last three weeks of treatment and by significantly lower drug consumption.
- the various tests carried out have shown that the tolerance of the IgG preparations according to the invention is always satisfactory and that an improvement in the clinical signs of the disease has been observed.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Les préparations à base d'IgG de l'invention présentent un titre en IgG 4 d'au moins 4% et un taux de chaînes polymère d'au moins 10%, leur titre en anticorps anti-allergènes anti-pollens et anti-acariens étant d'au moins 4 u/ml de préparation.The IgG preparations of the invention have an IgG 4 titer of at least 4% and a level of polymer chains of at least 10%, their titer of anti-allergen anti-pollen and anti-mite antibodies being at least 4 u / ml of preparation.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8503387 | 1985-03-07 | ||
FR8503387A FR2578425B1 (en) | 1985-03-07 | 1985-03-07 | IMMUNOGLOBULIN PREPARATIONS HAVING HIGH TITLES OF ANTI-ALLERGENIC BLOCKING ANTIBODIES, THEIR PREPARATION AND THEIR APPLICATIONS FOR THE TREATMENT OF ALLERGIES |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0215081A1 true EP0215081A1 (en) | 1987-03-25 |
Family
ID=9316976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19860901887 Withdrawn EP0215081A1 (en) | 1985-03-07 | 1986-03-07 | Preparations of immunoglobulines presenting high titres of blocking antibodies |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0215081A1 (en) |
JP (1) | JPS62502119A (en) |
FR (1) | FR2578425B1 (en) |
WO (1) | WO1986005099A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2646917A1 (en) * | 1989-05-12 | 1990-11-16 | Fond Nat Transfusion Sanguine | METHOD FOR DETERMINING ANTI-ALLERGEN SPECIFIC IGG ANTI-BODY, IGG4-RICH FRACTION OBTAINED ACCORDING TO THIS PROCESS AND PHARMACEUTICAL COMPOSITION CONTAINING THIS FRACTION |
EP0619323A1 (en) * | 1993-04-09 | 1994-10-12 | Schering-Plough | Human monoclonal antibodies and processes and materials for making such antibodies |
US10508133B2 (en) | 2013-10-18 | 2019-12-17 | Novasep Process | Purification of proteins |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK139056B (en) * | 1976-04-06 | 1978-12-11 | Nordisk Insulinlab | Method for recovering immunoglobulin suitable for intravenous administration. |
-
1985
- 1985-03-07 FR FR8503387A patent/FR2578425B1/en not_active Expired
-
1986
- 1986-03-07 WO PCT/FR1986/000075 patent/WO1986005099A1/en not_active Application Discontinuation
- 1986-03-07 EP EP19860901887 patent/EP0215081A1/en not_active Withdrawn
- 1986-03-07 JP JP50158986A patent/JPS62502119A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO8605099A1 * |
Also Published As
Publication number | Publication date |
---|---|
FR2578425A1 (en) | 1986-09-12 |
FR2578425B1 (en) | 1988-06-10 |
JPS62502119A (en) | 1987-08-20 |
WO1986005099A1 (en) | 1986-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0359593B2 (en) | Chromatographic separation of plasma proteins, particularly of factor VIII, of von Willebrand factor, of fibronectin and of fibrinogen | |
EP1968634B1 (en) | PROCESS FOR PREPARING AN IMMUNOGLOBULIN G (IgG) CONCENTRATE DEPLETED OF ANTI-A AND ANTI-B ANTIBODIES | |
HUE028581T2 (en) | Process for preparing an immunoglobulin composition | |
CA1339724C (en) | Anti-inflammatory factor, method of isolation, and use | |
CA2376335A1 (en) | Novel ig fractions having an immunomodulatory activity | |
CH648757A5 (en) | PROCESS FOR THE PREPARATION OF AN ALLERGEN TREATED WITH AN ALDEHYDE. | |
CA1090701A (en) | Drug for the treatment of acute or chronic viral hepatitis | |
WO1986005099A1 (en) | Preparations of immunoglobulines presenting high titres of blocking antibodies | |
HUE033586T2 (en) | Factor viii-derived peptides for use in the treatment of haemophilia a | |
CA2086101C (en) | Immune suppressive product from milk | |
EP2004233A1 (en) | Concentrate of chikungunya-specific immunoglobulins as medicine | |
FR2657784A1 (en) | CEREBRAL ENDOGENIC FACTOR, PROCESS FOR OBTAINING THERAPEUTIC AND DIAGNOSTIC APPLICATIONS. | |
Ring et al. | Improved compatibility of ALG therapy by application of aggregate free globulin | |
EP0100734B1 (en) | Process for the separation or purification of a sleep promoting factor from a biological source by immunological reaction of the antigen-antibody kind | |
JPH08505126A (en) | Preparation method of allergen extract and its manufacturing method | |
RU2238106C2 (en) | Intravenous anti-allergic immunoglobulin preparation and method for its preparing | |
BE897227A (en) | TREATMENT OF ALLERGIC DISORDERS | |
FR2655853A1 (en) | PROCESS FOR THE INTENSIVE CULTURE, IN VITRO, OF STRAINS OF BABESIA DIVERGENS, PROCESS FOR THE PREPARATION OF EXOANTIGENS AND A VACCINE CONTAINING SUCH ANTIGENS. | |
JPS606622A (en) | Purification of immunoglobulin | |
JPH07101879A (en) | Immunoglobulin pharmaceutical preparation and its production | |
FR2794460A1 (en) | Immunoglobulin fraction useful for treating autoimmune diseases, graft-versus-host disease, transplant rejection and neurological diseases | |
MX2008007149A (en) | Therapeutic vaccine | |
BE839872A (en) | PROTEIN HAVING ANALOGUE ACTIVITY TO THYMUS HORMONE AND ITS APPLICATIONS | |
FR2641538A1 (en) | COMPLEMENT INHIBITOR FACTOR, ITS CHARACTERIZATION AND ITS APPLICATIONS | |
JPH0375533B2 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19861030 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
17Q | First examination report despatched |
Effective date: 19890414 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19900508 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: STEINBUCH, MARION Inventor name: SOULIER, JEAN-PIERRE Inventor name: POUPOT, BERNARD |